CN100441176C - 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物 - Google Patents

测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物 Download PDF

Info

Publication number
CN100441176C
CN100441176C CNB028228731A CN02822873A CN100441176C CN 100441176 C CN100441176 C CN 100441176C CN B028228731 A CNB028228731 A CN B028228731A CN 02822873 A CN02822873 A CN 02822873A CN 100441176 C CN100441176 C CN 100441176C
Authority
CN
China
Prior art keywords
suramin
dosage
patient
dose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028228731A
Other languages
English (en)
Chinese (zh)
Other versions
CN1589138A (zh
Inventor
杰西·L·S·奥
M·吉尔劳姆·温特杰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1589138A publication Critical patent/CN1589138A/zh
Application granted granted Critical
Publication of CN100441176C publication Critical patent/CN100441176C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028228731A 2001-09-24 2002-09-24 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物 Expired - Fee Related CN100441176C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32470401P 2001-09-24 2001-09-24
US60/324,704 2001-09-24

Publications (2)

Publication Number Publication Date
CN1589138A CN1589138A (zh) 2005-03-02
CN100441176C true CN100441176C (zh) 2008-12-10

Family

ID=23264730

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028228731A Expired - Fee Related CN100441176C (zh) 2001-09-24 2002-09-24 测定联合疗法中使用的苏拉明的化学敏感化剂量的方法和组合物

Country Status (9)

Country Link
US (2) US20040180955A1 (cg-RX-API-DMAC7.html)
EP (1) EP1429713A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005508322A (cg-RX-API-DMAC7.html)
KR (1) KR20040062546A (cg-RX-API-DMAC7.html)
CN (1) CN100441176C (cg-RX-API-DMAC7.html)
AU (1) AU2002330088B2 (cg-RX-API-DMAC7.html)
CA (1) CA2461227C (cg-RX-API-DMAC7.html)
IL (1) IL161036A0 (cg-RX-API-DMAC7.html)
WO (1) WO2003026574A2 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007065016A2 (en) * 2005-12-02 2007-06-07 Au Jessie L S Methods and compositions to improve activity and reduce toxicity of stents
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo
JP7897560B2 (ja) * 2021-03-18 2026-07-30 学校法人産業医科大学 スラミンを含む組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219872A (zh) * 1996-05-24 1999-06-16 血管技术药物公司 治疗或预防身体通道疾病的组合物和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597830A (en) * 1994-12-20 1997-01-28 Warner-Lambert Company Combination chemotherapy
CA2281570C (en) * 1997-03-11 2003-09-23 Les Laboratoires Aeterna Inc. Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
CA2377385A1 (en) * 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1219872A (zh) * 1996-05-24 1999-06-16 血管技术药物公司 治疗或预防身体通道疾病的组合物和方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Nontoxic Doses of Suramin Enhance Activityof Paclitaxelagainst Lung Metastases. Song, S.et al.Cancer reaserch,Vol.61 No.8. 2001 *
Phase I Study of Suramin Combined with Doxorubicin in the Treatment of Androgen-independent Prostate Cancer. Tu,S et al.Clinical Cancer Reaserch,Vol.4 No.5. 1998 *
Surface area nomogram for acytotoxic drug regime:Acomputerised model. EDWARDS,A. et al.Pharmaceutical Journal,Vol.225 No.12. 1980 *
抗肿瘤药苏拉明钠. 许康华. 药学进展，第19卷第4期. 1995 *
苏拉明对肺癌血管生成的抑制作用. 王海东等. 第三军医大学学报，第23卷第5期. 2001 *

Also Published As

Publication number Publication date
JP2005508322A (ja) 2005-03-31
WO2003026574A2 (en) 2003-04-03
CA2461227A1 (en) 2003-04-03
HK1074167A1 (zh) 2005-11-04
US20110142794A1 (en) 2011-06-16
EP1429713A2 (en) 2004-06-23
EP1429713A4 (en) 2007-08-08
CN1589138A (zh) 2005-03-02
WO2003026574A3 (en) 2004-04-15
KR20040062546A (ko) 2004-07-07
AU2002330088B2 (en) 2009-09-03
CA2461227C (en) 2012-05-15
US20040180955A1 (en) 2004-09-16
US8580857B2 (en) 2013-11-12
IL161036A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
Ardalan et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.
Lana et al. Slow release cisplatin combined with radiation for the treatment of canine nasal tumors
US8580857B2 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
Duffy et al. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma
Iyer et al. A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study
Vokes et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Morris et al. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
Floyd et al. Clearance of continuously infused 5-fluorouracil in adults having lung or gastrointestinal carcinoma with or without hepatic metastases
Ajani et al. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane
Alhalabi et al. Comparative effectiveness analysis of treatment strategies for surgically RESECTABLE neuroendocrine carcinoma of the urinary tract
Klyosov et al. DAVANAT®(GM-CT-01) and colon cancer: preclinical and clinical (Phase I and II) studies
AU2002330088A1 (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
US20220387483A1 (en) Use of iodide compounds for the treatment and prevention of chemotherapy-associated cachexia and cardiotoxicity
Patel et al. A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer
Morgan Jr et al. Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels
Plummer et al. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor
KR20200110452A (ko) 담도암을 치료하기 위한 방법 및 조합 요법
Mammadova et al. Screening of the small molecule library of Meinox enables the identification of anticancer compounds in pathologically distinct cancers
Mellett Pharmacodynamic and pharmacokinetic measurements of antitumor agents
Di Costanzo et al. High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer
Takimoto Basic pharmacokinetics and pharmacodynamic principles
HK1074167B (en) Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
Alberts et al. Pemetrexed and Oxaliplatin for metastatic colorectal cancer: Results of a phase I Mayo Cancer Center Research Consortium trial, MC0248
Rajnee et al. Comparative Evaluation of Renal Parameters in Patients Treated with Cisplatin, Carboplatin, and Oxaliplatin
TaLa et al. A mathematical model to study the effect of drug kinetics on the drug-induced resistance in tumor growth dynamics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074167

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1074167

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081210

Termination date: 20170924

CF01 Termination of patent right due to non-payment of annual fee